Amgen (AMGN) Stock Forecast & Price Target

Compare

6,761 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMGN Analyst Ratings

Moderate Buy

11 Buy

7 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMGN Stock 12 Month Forecast

Average Price Target

$345.87

▲(4.77% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $345.87 with a high forecast of $425.00 and a low forecast of $272.00. The average price target represents a 4.77% change from the last price of $330.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"251":"$251","426":"$426","294.75":"$294.8","338.5":"$338.5","382.25":"$382.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$425.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":345.87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$345.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$272.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[251,294.75,338.5,382.25,426],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.31,334.8246153846154,342.33923076923077,349.8538461538462,357.36846153846153,364.88307692307694,372.3976923076923,379.9123076923077,387.42692307692306,394.94153846153847,402.4561538461538,409.97076923076924,417.48538461538465,{"y":425,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.31,328.7376923076923,330.1653846153846,331.5930769230769,333.02076923076925,334.4484615384615,335.87615384615384,337.30384615384617,338.7315384615385,340.15923076923076,341.5869230769231,343.0146153846154,344.4423076923077,{"y":345.87,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.31,323.05538461538464,318.8007692307692,314.54615384615386,310.29153846153844,306.0369230769231,301.7823076923077,297.5276923076923,293.2730769230769,289.01846153846157,284.76384615384615,280.5092307692308,276.25461538461536,{"y":272,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":252.423,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.422,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.759,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.646,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277.054,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":284.122,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.141,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.405,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.672,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.386,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.316,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":337.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$425.00

Average Price Target$345.87

Lowest Price Target$272.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

UBS

$317→$380

Buy

15.11%

Upside

Upgraded

01/07/26

Amgen upgraded to Buy from Neutral at UBSAmgen upgraded to Buy from Neutral at UBS

David Amsellem

Piper Sandler

$381

Buy

15.42%

Upside

Reiterated

01/07/26

Amgen (AMGN) Receives a Buy from Piper Sandler

Geoff Meacham

Citi

$315

Hold

-4.58%

Downside

Reiterated

01/05/26

Citi Sticks to Their Hold Rating for Amgen (AMGN)

Courtney Breen

Bernstein

$335

Buy

1.48%

Upside

Reiterated

12/19/25

Amgen (AMGN) Receives a Buy from Bernstein

Gregory Renza

Truist Financial

Hold

―

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Novan (NASDAQ: NOVN)

Terence Flynn

Morgan Stanley

$329→$304

Hold

-7.91%

Downside

Reiterated

12/12/25

Amgen price target lowered to $304 from $329 at Morgan StanleyAmgen price target lowered to $304 from $329 at Morgan Stanley

Louise Chen

Scotiabank

$385

Buy

16.63%

Upside

Reiterated

12/11/25

Scotiabank Remains a Buy on Amgen (AMGN)

Mohit Bansal

Wells Fargo

$300→$325

Hold

-1.55%

Downside

Reiterated

12/10/25

Wells Fargo Remains a Hold on Amgen (AMGN)

Morten Herholdt

HSBC

$381→$425

Buy

28.74%

Upside

Reiterated

12/10/25

Amgen price target raised to $425 from $381 at HSBCAmgen price target raised to $425 from $381 at HSBC

Hans Engel

Erste Group

Buy

―

Upgraded

12/05/25

Amgen upgraded to Buy from Hold at Erste GroupAmgen upgraded to Buy from Hold at Erste Group

Evan Seigerman

BMO Capital

$335→$372

Buy

12.69%

Upside

Reiterated

12/03/25

Amgen price target raised to $372 from $335 at BMO CapitalAmgen price target raised to $372 from $335 at BMO Capital

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$280

Hold

-15.18%

Downside

Reiterated

11/20/25

Amgen (AMGN) Gets a Hold from Mizuho Securities

Carter Gould

Cantor Fitzgerald

$305→$315

Hold

-4.58%

Downside

Reiterated

11/06/25

Amgen price target raised to $315 from $305 at Cantor FitzgeraldAmgen price target raised to $315 from $305 at Cantor Fitzgerald

Tim Anderson

Bank of America Securities

$272

Sell

-17.60%

Downside

Reiterated

11/05/25

Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays

Matt Phipps

William Blair

Buy

―

Reiterated

11/05/25

Amgen's Strong Q3 Performance and Promising Pipeline Justify Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

UBS

$317→$380

Buy

15.11%

Upside

Upgraded

01/07/26

Amgen upgraded to Buy from Neutral at UBSAmgen upgraded to Buy from Neutral at UBS

David Amsellem

Piper Sandler

$381

Buy

15.42%

Upside

Reiterated

01/07/26

Amgen (AMGN) Receives a Buy from Piper Sandler

Geoff Meacham

Citi

$315

Hold

-4.58%

Downside

Reiterated

01/05/26

Citi Sticks to Their Hold Rating for Amgen (AMGN)

Courtney Breen

Bernstein

$335

Buy

1.48%

Upside

Reiterated

12/19/25

Amgen (AMGN) Receives a Buy from Bernstein

Gregory Renza

Truist Financial

Hold

―

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Novan (NASDAQ: NOVN)

Terence Flynn

Morgan Stanley

$329→$304

Hold

-7.91%

Downside

Reiterated

12/12/25

Amgen price target lowered to $304 from $329 at Morgan StanleyAmgen price target lowered to $304 from $329 at Morgan Stanley

Louise Chen

Scotiabank

$385

Buy

16.63%

Upside

Reiterated

12/11/25

Scotiabank Remains a Buy on Amgen (AMGN)

Mohit Bansal

Wells Fargo

$300→$325

Hold

-1.55%

Downside

Reiterated

12/10/25

Wells Fargo Remains a Hold on Amgen (AMGN)

Morten Herholdt

HSBC

$381→$425

Buy

28.74%

Upside

Reiterated

12/10/25

Amgen price target raised to $425 from $381 at HSBCAmgen price target raised to $425 from $381 at HSBC

Hans Engel

Erste Group

Buy

―

Upgraded

12/05/25

Amgen upgraded to Buy from Hold at Erste GroupAmgen upgraded to Buy from Hold at Erste Group

Evan Seigerman

BMO Capital

$335→$372

Buy

12.69%

Upside

Reiterated

12/03/25

Amgen price target raised to $372 from $335 at BMO CapitalAmgen price target raised to $372 from $335 at BMO Capital

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$280

Hold

-15.18%

Downside

Reiterated

11/20/25

Amgen (AMGN) Gets a Hold from Mizuho Securities

Carter Gould

Cantor Fitzgerald

$305→$315

Hold

-4.58%

Downside

Reiterated

11/06/25

Amgen price target raised to $315 from $305 at Cantor FitzgeraldAmgen price target raised to $315 from $305 at Cantor Fitzgerald

Tim Anderson

Bank of America Securities

$272

Sell

-17.60%

Downside

Reiterated

11/05/25

Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays

Matt Phipps

William Blair

Buy

―

Reiterated

11/05/25

Amgen's Strong Q3 Performance and Promising Pipeline Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+4.49%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.49% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

12/13 ratings generated profit

Average Return

+13.10%

reiterated a buy rating 5 days ago

Copying David Amsellem's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +13.10% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+19.69%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +19.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMGN Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMGN has received 23 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. AMGN average Analyst price target in the past 3 months is 345.87.

Each month's total comprises the sum of three months' worth of ratings.

AMGN Financial Forecast

AMGN Earnings Forecast

Next quarter’s earnings estimate for AMGN is $4.73 with a range of $4.05 to $5.74. The previous quarter’s EPS was $5.64. AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Sales Forecast

Next quarter’s sales forecast for AMGN is $9.46B with a range of $8.98B to $9.87B. The previous quarter’s sales results were $9.59B. AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AMGN has Performed in-line its overall industry.

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 345.87.

What is AMGN’s upside potential, based on the analysts’ average price target?

Amgen has 4.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMGN a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 7 hold ratings and 1 sell ratings.

What is Amgen’s price target?

The average price target for Amgen is 345.87. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $425.00 ,the lowest forecast is $272.00. The average price target represents 4.77% Increase from the current price of $330.11.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of AMGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amgen (AMGN) Stock Forecast & Price Target

AMGN Analyst Ratings

AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMGN Analyst Recommendation Trends

AMGN Financial Forecast

AMGN Earnings Forecast

AMGN Sales Forecast

AMGN Stock Forecast FAQ

Detailed List of Analyst Forecasts